About Irritable Bowel Syndrome
Irritable bowel syndrome is a common disorder of the digestive system causing abdominal cramps, discomfort, bloating, constipation, and diarrhea. Inflammatory bowel disease, which is a chronic disease with recurrent immune response and inflammation of the GI tract, is sometimes confused with irritable bowel syndrome. The symptoms of irritable bowel syndrome generally appear in a patient aged around 30 years. According to the CDC, prominent symptoms of irritable bowel syndrome include severe bloating, severe stomach cramps or abdominal pain, lower back pain, groin pain, heartburn, acidity, shooting pain in the legs, and lightheadedness after eating.
TechNavio's analysts forecast the Global Irritable Bowel Syndrome market to grow at a CAGR of 14.04 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Irritable Bowel Syndrome market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of irritable bowel syndrome.
TechNavio's report, Global Irritable Bowel Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Irritable Bowel Syndrome market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Actavis
• Astellas Pharma
• Nestle
• Takeda Pharmaceutical
Other Prominent Vendors
• Abbott
• Alba Therapeutics
• Alfa Wassermann
• Alizyme
• Almirall
• AltheRx Pharmaceuticals
• Ardelyx
• AstraZeneca
• Bayer
• Bristol Myers Squibb
• Dainippon Sumitomo Pharma
• Dong-A Socio Holdings
• Drais Pharmaceuticals
• Dynogen
• gIcare Pharma
• GlaxoSmithKline
• Hanmi Pharmaceuticals
• ImmusanT
• Ironwood
• Janssen
• Lexicon Pharmaceuticals
• Menarini
• MicroDose Therapeutx
• Norgine
• Novartis
• Ocera Therapeutics
• Ono Pharmaceutical
• Par Pharmaceutical
• Pfizer
• Pharmos
• Protagonist Therapeutics
• RaQualia Pharma
• Rottapharm
• Salix
• Seldar Pharma
• Shire
• SK Chemicals
• SOFAR
• Synergy Pharmaceuticals
• Synthetic Biologics
• Tioga Pharmaceuticals
• Tsumura
• Yuhan
Market Driver
• Presence of Unmet Need
• For a full, detailed list, view our report
Market Challenge
• High Cost of Therapy
• For a full, detailed list, view our report
Market Trend
• Rise in Public Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Linzess
04.1.2 Irribow/Irribow OD
04.1.3 Lotronex
04.1.4 Amitiza
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Mechanism of Action
08.1 Guanylate Cyclase Receptor-C Agonist
08.2 5HT3 Antagonist
08.3 Chloride Channel Activator
08.4 Others
09. Market Segmentation by Dosage Form
09.1 Solid
09.2 Liquid
10. Market Segmentation by Indication
10.1 IBS-C
10.2 IBS-D
11. Market Segmentation by End User Gender
11.1 Female
11.2 Both
12. Geographical Segmentation
13. Rate of Incidence and Prevalence
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Takeda
21.2.2 Nestle
21.2.3 Actavis
21.2.4 Astellas
21.3 Other and Future Prominent Vendors
22. Pipeline Portfolio
23. Key Vendor Analysis
23.1 Actavis
23.1.1 Key Facts
23.1.2 Business Description
23.1.3 Business Segmentation
23.1.4 Business Segmentation by Revenue 2012 and 2013
23.1.5 Sales by Geography
23.1.6 Business Strategy
23.1.7 Key Information
23.1.8 SWOT Analysis
23.2 Astellas Pharma
23.2.1 Key Facts
23.2.2 Business Overview
23.2.3 Product Segmentation
23.2.4 Product Segmentation by Revenue 2012 and 2013
23.2.5 Geographical Segmentation by Revenue 2013
23.2.6 Business Strategy
23.2.7 Recent Developments
23.2.8 SWOT Analysis
23.3 Nestlé
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Business Segmentation by Revenue 2013
23.3.4 Business Segmentation by Revenue 2012 and 2013
23.3.5 Geographical Segmentation by Revenue 2013
23.3.6 Business Strategy
23.3.7 Recent Developments
23.3.8 SWOT Analysis
23.4 Takeda Pharmaceuticals
23.4.1 Key Facts
23.4.2 Business Overview
23.4.3 Business Segmentation by Revenue 2013
23.4.4 Business Segmentation by Revenue 2013
23.4.5 Geographical Segmentation by Revenue 2013
23.4.6 Business Strategy
23.4.7 Recent Developments
23.4.8 SWOT Analysis
24. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Irritable Bowel Syndrome Market 2014-2019 (US$ million)
Exhibit 3: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action
Exhibit 4: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action 2014
Exhibit 5: Global Irritable Bowel Syndrome Market Segmentation by Dosage Form
Exhibit 6: Global Irritable Bowel Syndrome Market Segmentation by Dosage Form 2014
Exhibit 7: Global Irritable Bowel Syndrome Market Segmentation by Indication
Exhibit 8: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action 2014
Exhibit 9: Global Irritable Bowel Syndrome Market Segmentation by End User Gender
Exhibit 10: Global Irritable Bowel Syndrome Market Segmentation by End User Gender 2014
Exhibit 11: Global Irritable Bowel Syndrome Market by Geographical Segmentation 2014
Exhibit 12: Prevalence of Irritable Bowel Syndrome in Japanese Females, by Type
Exhibit 13: Prevalence of Irritable Bowel Syndrome in Japanese Males, by Type
Exhibit 14: Global Irritable Bowel Syndrome Market Share Analysis 2014
Exhibit 15: Pipeline Portfolio of the Drug Candidates for Irritable Bowel Syndrome
Exhibit 16: Clinical Trials of Irritable Bowel Syndrome Drugs by Geography
Exhibit 17: Clinical Trials of Irritable Bowel Syndrome Drugs by Geography
Exhibit 18: Percentage of Clinical Trial Molecules in Each Phase
Exhibit 19: Actavis: Business Segmentation 2013
Exhibit 20: Actavis: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 21: Actavis : Sales by Geography (in US$ million)
Exhibit 22: Astellas Pharma: Product Segmentation 2013
Exhibit 23: Astellas Pharma : Product Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 24: Astellas Pharma: Geographical Segmentation by Revenue 2013
Exhibit 25: Nestlé: Business Segmentation by Revenue 2013
Exhibit 26: Nestlé: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 27: Nestlé: Geographical Segmentation by Revenue 2013
Exhibit 28: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
Exhibit 29: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
Exhibit 30: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
